No definition available.
Malignant neoplasm of thymus, excluding all cancers (controls excluding all cancers)
C3_THYMUS_EXALLC
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
141 |
4. Check minimum number of eventsNone |
141 |
5. Include endpointsNone |
141 |
6. Filter based on genotype QC (FinnGen only) |
141 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of thymus, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of respiratory system and intrathoracic organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 141 | 64 | 77 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.03 |
| Median age at first event (years) | 62.20 | 61.56 | 62.73 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 99
- Matched controls
- 989
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D38.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Mediastinum
+∞
52.9
46
*
C37
ICD-10 Finland
Malignant neoplasm of thymus
+∞
46.6
41
*
GEC24
NOMESCO Finland
Thoracoscopic thymectomy
+∞
45.3
40
*
D38.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thymus
+∞
44.1
39
*
D15.0
ICD-10 Finland
Benign neoplasm: Thymus
+∞
32.0
29
*
8580/3-C37.9
ICD-O-3
Thymoma, NOS, of thymus
+∞
32.0
29
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
41.8
31.5
39
15
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
19.7
28.1
45
40
130
Kela drug reimbursment
Malignant tumour
+∞
26.2
24
*
H02AB02
ATC
dexamethasone; systemic
76.9
25.6
28
5
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
21.6
20
*
GEC23
NOMESCO Finland
Transsternal thymectomy
+∞
20.5
19
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
19.4
18
*
8582/3-C37.9
ICD-O-3
Thymoma, type AB of thymus
+∞
19.4
18
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
7.5
18.7
74
281
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
18.3
17
*
GD1AD
NOMESCO Finland
Thorax CT examination
23.4
17.6
25
14
JN4BD
NOMESCO Finland
Extensive body CT
17.2
17.5
28
22
ZXC96
NOMESCO Finland
Robot assisted procedure
202.8
17.1
17
*
XX3DW
NOMESCO Finland
Time consuming IT work
21.3
15.2
22
13
WX408
NOMESCO Finland
General anesthesy, balanced
6.1
15.0
53
158
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
15.0
14
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
15.0
14
*
WF002
NOMESCO Finland
Radical radiotherapy
174.7
14.9
15
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
174.7
14.9
15
*
A03FA01
ATC
metoclopramide; systemic, rectal
7.8
14.3
36
67
A04AA02
ATC
granisetron; systemic, transdermal
161.2
13.8
14
*
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
47.0
13.6
16
*
B01AB05
ATC
enoxaparin; parenteral
5.7
13.3
47
136
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
6.9
13.0
36
76
GEB30
NOMESCO Finland
Mediastinotomy and excision of lesion
+∞
12.8
12
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
12.8
12
*
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
148.0
12.8
13
*
G70.0
ICD-10 Finland
Myasthenia gravis
148.0
12.8
13
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
11.7
11
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
11.7
11
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
11.7
11
*
A04AA01
ATC
ondansetron; systemic, rectal
29.1
11.5
15
6
WX302
NOMESCO Finland
Thoracal epidural anesthesy
20.9
11.2
16
9
N07AA02
ATC
pyridostigmine; systemic
122.4
10.6
11
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
10.6
10
*
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
+∞
10.6
10
*
Z51.5
ICD-10 Finland
Palliative care
44.9
10.2
12
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
10.9
10.1
19
21
108
Kela drug reimbursment
Myasthenia gravis
110.1
9.6
10
*
L03AA02
ATC
filgrastim; parenteral
110.1
9.6
10
*
R4110
NOMESCO Finland
Physiotherapy
4.3
9.6
43
150
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
9.5
9
*
L03AA13
ATC
pegfilgrastim; parenteral
+∞
9.5
9
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
9.5
9
*
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
40.8
9.2
11
*
JN4AD
NOMESCO Finland
Body CT examination
16.4
8.5
13
9
A04AD12
ATC
aprepitant; systemic
+∞
8.4
8
*
N02AA05
ATC
oxycodone; systemic
6.2
8.4
23
46
WZC30
NOMESCO Finland
Teaching
6.2
8.4
23
46
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.7
8.3
45
180
WX402
NOMESCO Finland
General anaesthesia
4.9
8.2
28
73
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.8
8.1
41
154
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
7.9
8.0
18
27
JN6AD
NOMESCO Finland
CT of torso and neck
86.3
7.5
8
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
7.4
7
*
8583/3-C37.9
ICD-O-3
Thymoma, type B1 of thymus
+∞
7.4
7
*
116
Kela drug reimbursment
Prostate cancer
+∞
7.4
7
*
8585/3-C37.9
ICD-O-3
Thymoma, type B3 of thymus
+∞
7.4
7
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
7.4
7
*
8581/3-C37.9
ICD-O-3
Thymoma, type A of thymus
+∞
7.4
7
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.8
6.8
31
106
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
15.7
6.5
10
7
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
19.6
6.4
9
5
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
28.7
6.3
8
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
6.3
6
*
D15.2
ICD-10 Finland
Benign neoplasm: Mediastinum
+∞
6.3
6
*
L01BC06
ATC
capecitabine; oral
+∞
6.3
6
*
8070/3-C37.9
ICD-O-3
Squamous cell carcinoma, NOS, of thymus
+∞
6.3
6
*
C38.1
ICD-10 Finland
Malignant neoplasm: Anterior mediastinum
+∞
6.3
6
*
WW500
NOMESCO Finland
Blood transfusion
16.3
6.0
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
75
213
6.39
27.30
2.7
1.9
—
—
—
0
0
121
582
8.61
23.00
18.9
6.1
3.9
4.2
e9/l
0.89
109
511
34
51
8.47
22.83
3.3
1.8
2.1
8.2
ug/l
0.53
24
39
104
451
5.98
21.84
5.3
3.5
—
—
—
0
0
102
482
5.04
17.96
12.9
5.3
1.2
1.2
mmol/l
0.07
92
413
17
15
12.75
16.52
1.4
1.1
—
—
—
0
0
81
345
4.17
15.86
3.9
2.7
—
—
—
0
0
28
50
6.74
15.79
11.7
5.3
25.6
25.4
mmol/l
0.09
28
50
18
20
10.17
14.99
2.4
2.8
4.0
3.6
g/l
0.25
18
20
27
54
5.95
13.52
20.2
7.3
0.6
0.7
%
0.55
27
54
40
115
4.46
13.14
14.6
7.1
5.4
5.3
kpa
0.27
40
109
40
115
4.46
13.14
14.6
7.1
13.6
11.2
kpa
1.32
40
110
27
56
5.73
12.99
20.0
7.3
1.2
1.6
%
0.82
27
56
25
49
5.99
12.75
18.3
7.0
24.9
25.1
mmol/l
0.11
25
44
65
271
3.59
12.48
3.6
2.6
0.2
0.4
e6/l
0.96
54
187
16
6
29.77
12.35
4.9
1.5
4.7
4.6
nmol/l
—
16
6
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
23
8.27
12.12
2.8
1.6
0.3
0.4
u/ml
—
10
13
69
314
3.35
11.28
9.8
2.0
2.4
2.4
mmol/l
0.18
64
265
45
160
3.66
10.82
3.5
2.5
5.1
2.6
e6/l
0.44
31
77
36
113
3.94
10.33
2.2
2.5
22.8
26.7
%
0.75
36
102
17
28
6.77
10.18
2.2
1.7
87.9
90.2
%
0.13
17
28
15
9
18.45
10.12
2.9
1.4
26.0
19.3
ug/l
—
15
9
46
173
3.46
10.07
3.5
2.3
1.8
1.0
e6/l
0.55
32
90
52
221
3.14
9.22
1.8
1.8
3.1
3.0
mg/l
0.06
46
183
50
223
2.92
7.98
2.0
1.7
1.3
1.1
mg/l
0.15
40
168
12
19
6.81
7.37
1.1
1.4
—
—
—
0
0
10
13
8.20
7.21
1.3
1.5
—
—
—
0
0
133
1121
4.28
5.53
32.4
10.8
31.8
23.3
mg/l
2.30
128
846
8
5
16.83
5.47
2.5
1.0
—
—
—
0
0
13
30
4.67
5.42
3.0
4.3
—
—
—
0
0
34
153
2.61
5.12
1.9
1.5
—
—
—
0
0
9
10
9.52
4.86
1.0
1.0
—
—
—
0
0
43
232
2.23
4.29
3.1
3.6
45.7
209.7
ng/l
1.59
35
186
18
63
3.13
4.24
6.0
4.6
68.3
92.8
ng/l
1.18
18
57
117
932
2.50
4.18
37.8
12.9
14.2
13.6
%
3.53
117
916
17
58
3.20
4.17
1.9
1.2
—
—
—
0
0
15
49
3.31
3.94
3.3
2.1
38.5
42.2
u/l
0.32
15
43
7
9
8.11
3.60
1.4
1.1
—
—
—
0
0
23
102
2.50
3.52
1.7
1.6
—
—
—
0
0
8
15
5.58
3.24
1.9
1.5
—
—
—
0
0
8
15
5.58
3.24
1.4
1.1
—
—
—
0
0
12
39
3.27
3.17
3.9
1.8
185.2
420.7
ug/l
0.68
12
34
73
520
1.84
3.14
4.7
4.4
0.0
0.0
estimate
0.00
13
84
73
527
1.80
2.95
3.4
3.2
0.0
0.0
estimate
0.00
13
82
9
22
4.29
2.93
1.0
1.3
—
—
—
0
0
6
9
6.90
2.89
2.7
4.3
—
—
—
0
0
22
105
2.30
2.87
1.9
1.6
—
—
—
0
0
8
18
4.64
2.84
1.4
1.1
—
—
—
0
0
135
1227
3.35
2.78
36.8
12.4
79.8
78.7
umol/l
0.14
135
1227
7
14
5.20
2.76
1.4
1.6
—
—
—
0
0
62
433
1.77
2.75
4.4
3.2
51.9
45.5
ng/l
0.09
51
290
22
109
2.21
2.64
2.5
2.0
8.0
10.4
umol/l
0.23
22
95
70
514
1.72
2.56
3.4
3.2
0.0
0.0
estimate
0.00
11
85
18
83
2.34
2.54
4.6
1.9
82.5
62.8
ml/min/173m2
—
10
29
32
187
1.92
2.48
1.3
1.2
14.2
22.6
iu/ml
—
8
58
95
765
1.74
2.43
2.9
2.9
57.2
49.5
u/l
0.43
90
720
106
1196
0.54
2.37
4.2
5.1
2.7
2.8
mmol/l
0.35
101
1109
13
53
2.60
2.35
1.5
1.5
—
—
—
0
0
5
9
5.71
2.23
2.4
1.2
—
—
—
0
0
5
9
5.71
2.23
1.0
1.0
—
—
—
0
0
5
9
5.71
2.23
1.2
1.4
—
—
—
0
0
49
341
1.67
2.10
3.7
2.1
63.9
58.2
u/l
0.36
49
312
5
10
5.14
2.09
1.2
1.4
—
—
—
0
0
5
10
5.14
2.09
1.0
1.3
—
—
—
0
0
6
15
4.13
2.06
1.0
1.1
189.3
53.9
pmol/l
—
6
15
6
15
4.13
2.06
1.5
1.0
—
—
—
0
0
105
1177
0.58
2.00
3.8
4.5
4.6
4.7
mmol/l
0.08
99
1094
5
11
4.67
1.96
1.6
1.2
—
—
—
0
0
5
11
4.67
1.96
1.6
1.2
—
—
—
0
0
5
11
4.67
1.96
1.6
1.2
—
—
—
0
0
6
17
3.64
1.86
1.5
2.2
—
—
—
0
0
5
12
4.28
1.84
1.2
1.0
—
—
—
0
0
105
1171
0.60
1.82
3.8
4.4
1.4
1.4
mmol/l
0.05
100
1083
121
1079
1.86
1.80
29.8
9.7
83.8
80.7
ml/min/173m2
0.89
115
862
11
48
2.40
1.75
4.0
1.1
—
—
—
0
0
5
13
3.94
1.73
1.6
1.0
—
—
—
0
0
17
91
1.99
1.69
2.6
3.1
—
—
—
0
0
8
31
2.67
1.68
1.9
1.5
—
—
—
0
0
16
84
2.02
1.67
2.6
3.0
190.9
117.3
ng/l
0.81
16
76
5
14
3.66
1.63
1.6
1.0
—
—
—
0
0
8
33
2.51
1.56
2.0
1.5
—
—
—
0
0
5
15
3.41
1.53
1.2
1.2
—
—
—
0
0
5
15
3.41
1.53
1.2
1.2
—
—
—
0
0
9
37
2.53
1.51
2.1
1.5
—
—
—
0
0
14
73
2.02
1.50
1.6
1.3
—
—
—
0
0
9
38
2.46
1.48
4.2
1.1
34.5
38.5
g/l
—
9
32
5
17
3.01
1.37
1.0
1.1
—
—
—
0
0
25
164
1.64
1.32
1.1
1.4
—
—
—
0
0
5
18
2.84
1.29
1.0
1.4
—
—
—
0
0
5
18
2.84
1.29
1.0
1.2
—
—
—
0
0
5
19
2.69
1.22
1.0
1.3
—
—
—
0
0
103
1127
0.68
1.16
3.4
4.0
1.3
1.3
mmol/l
0.02
98
1035
26
179
1.55
1.13
1.2
1.3
2.4
6.7
u/ml
—
8
67
135
1285
2.19
1.11
44.9
16.2
130.1
138.7
g/l
7.42
135
1260
53
430
1.37
0.99
1.7
1.8
86.7
92.7
pmol/l
0.53
34
203
7
37
1.94
0.95
1.7
1.4
—
—
—
0
0
49
402
1.34
0.84
3.5
3.3
—
—
—
0
0
113
1049
1.39
0.79
35.2
11.5
38.2
41.0
%
2.79
88
758
35
277
1.35
0.75
3.9
3.4
0.0
0.0
estimate
—
10
82
5
24
2.12
0.75
1.0
1.1
—
—
—
0
0
14
93
1.56
0.72
5.4
1.7
342.1
377.3
nmol/l
0.41
14
83
91
827
1.28
0.69
3.6
3.6
15.2
14.8
pmol/l
0.79
84
749
8
50
1.64
0.62
5.8
2.0
1.3
1.2
%
—
8
50
10
65
1.58
0.57
4.7
2.9
1.2
1.2
mmol/l
—
10
56
111
1046
1.29
0.55
4.4
4.3
1.9
1.9
mu/l
0.01
105
956
119
1136
1.30
0.49
4.3
4.4
5.8
6.0
mmol/l
1.11
111
1041
7
50
1.42
0.45
1.0
1.0
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
14
110
1.30
0.33
2.1
1.8
—
—
—
0
0
32
362
0.85
0.30
4.5
3.3
20.9
24.9
%
1.39
18
160
7
57
1.24
0.29
2.4
3.4
4.0
4.6
pmol/l
—
7
51
0
12
0.00
0.21
0.0
2.3
—
35.6
—
0
5
12
140
0.84
0.16
1.6
1.4
—
—
—
0
0
9
105
0.85
0.13
1.6
1.7
—
—
—
0
0
21
225
0.92
0.08
1.1
1.3
1.6
1.0
u/ml
—
6
59
13
136
0.95
0.00
16.5
6.9
—
—
—
0
0
69
692
0.99
0.00
2.8
2.8
—
—
—
0
0
25
248
1.01
0.00
3.6
2.4
0.9
0.7
ug/l
0.25
19
155
10
98
1.02
0.00
2.1
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
106.4
—
0
5
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_THYMUS_EXALLC – Malignant neoplasm of thymus, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).